Chia Tai Tianqing, a China-based pharmaceutical company, has entered into a strategic partnership with Fudan University Shanghai Cancer Center to intensify their collaboration on clinical trials for innovative drugs. The agreement leverages Chia Tai Tianqing’s comprehensive industrial chain strength in scientific and technological innovation and the Shanghai Cancer Center’s leading disciplinary expertise and extensive medical services. Together, they aim to deepen strategic cooperation in various fields, including scientific research, talent development, hospital management, and platform construction. This alliance is designed to advance clinical and translational medicine research, enhance precision tumor treatments, meet public health demands, and stimulate the growth of the pharmaceutical industry.
Under this partnership, the two entities have implemented over 20 programs across 15 departments, encompassing a range of oncology specialties such as gynecology, urology, and lymphoma. The fruits of their labor include two products that have received market approval, with another undergoing review for New Drug Application (NDA), demonstrating the tangible progress and potential impact of their collaborative efforts.- Flcube.com
